1. Mayhall CG. Prevention and control of vancomycin resistance in Gram-positive coccal microorganism: fire prevention and fire fighting. Infect Control Hosp Epidemiol. 1996; 17:353-5.10.2307/30141132
2. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997; 350:1670-3.10.1016/S0140-6736(97)07324-8
3. Centers for Disease Control and Prevention. Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan 1996. Morbl Mortal Wkly Rep. 1997. 46:624-6.
4. Rybak MJ, Chin JN, Lau K, Sader KH, Jones RN. Increasing prevalence of glycopeptide heteroresistant S. sureus from the Detroit metropolitan area over a 20-year period (1986-2006). Abstract 17th Eur Congr Clin Microbiol Infect Dis (ECCMID), 2007; 032.10.1016/S0924-8579(07)70031-6
5. Ploy MC, Grelaud C, Martin CC, de Lumley L, Dennis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet. 1998. 351:1212.10.1016/S0140-6736(05)79166-2
7. Trakulsomboon S. Danchaivijitr S, Rongrungruang Y, Dhiraputra C, Susaemgrat W, Ito T, et al. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. J Clin Microbiol. 1999; 39:591-5.10.1128/JCM.39.2.591-595.20018778111158112
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteen informational supplement. Approved standard M100-S16. Clinical and Laboratory Standards Institute, Wayne, USA. 2006.
9. Howe RA, Noel AR, Bowker KE. 2003. The prevalence of heterogeneously vancomycin intermediate Staphylococcus aureus (hVISA) in the USA. Abstract 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2003; abstr. C2-1828.
10. Delgado AJ, Riordan T, Lamichhane-Khadka R, Winnett DC, Jimenez J, Robinson K, et al. Heterovancomycin- intermediate methicillin-resistant Staphylococcus aureus isolate from a medical center in Las Cruces, New Mexico. J Clin Microbiol. 2007; 45: 1325-9. 10.1128/JCM.02437-06186582917267639
11. Goldstein F. The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus. J Antimicrob Chemother. 2007; 59:1-4.10.1093/jac/dkl42917068009
13. Walsh TR, Bolmström A, Qwärnström A, Ho P, Wootton M, Howe RA, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol. 2001; 39:2439-2444.10.1128/JCM.39.7.2439-2444.20018816711427551
14. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that aerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Villanova, USA.
15. Bernard L, Vaudaux P, Rohner P, Huggler E, Armanet M, Pittet D, et al. Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains. J Microbiol Methods. 2004; 57:231-9.10.1016/j.mimet.2004.01.01215063063
16. Wootton M, MacGowan AP, Walsh TR, Howe RA. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol. 2007; 45:329-32.10.1128/JCM.01508-06182900617108069
17. Lulitanond A, Chanawong A, Sribenjalux P, Kaewkes W, Vorachit M, Chongtrakool P, et al. Detection of heterogeneous, intermediate-vancomycin-resistant Staphylococcus aureus (hVISA) using lowconcentration vancomycin disks. Southeast Asian J Trop Med Public Health. 2006; 37:761-7.